AB Science is developing two main compounds Masitinib and AB8939

Signature of a 15.0 million financing deal with the European Investment Bank

November 30, 2020

30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19

Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT

November 16, 2020

16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT

Financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares

October 29, 2020

29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares

Positive top-line Phase 3 results for oral masitinib in severe asthma

October 20, 2020

20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma

Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society symposium

October 13, 2020

13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020

First half of 2020 results

September 30, 2020

30/09/2020 – AB Science reports its revenues for the first half of 2020

positive phase 2B/3 readouts with masitinib

publications in peer-reviewed journals

patients enrolled in masitinib studies